Predicting response to benralizumab in patients with COPD: a plain language summary of publication of the GALATHEA and TERRANOVA studies
Summary What is this summary about? ● This is a plain language summary of two articles originally published in The New England Journal of Medicine and The Lancet Respiratory Medicine . These articles presented the results of GALATHEA and TERRANOVA, two clinical studies that took place across 41 coun...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-03-01
|
| Series: | Therapeutic Advances in Respiratory Disease |
| Online Access: | https://doi.org/10.1177/17534666241312060 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Summary What is this summary about? ● This is a plain language summary of two articles originally published in The New England Journal of Medicine and The Lancet Respiratory Medicine . These articles presented the results of GALATHEA and TERRANOVA, two clinical studies that took place across 41 countries. ○ GALATHEA and TERRANOVA measured how patients’ COPD changed from before their first benralizumab (10, 30, or 100 mg) injection, to after 56 weeks of treatment. ○ In both studies, benralizumab was compared with placebo . ○ To see whether benralizumab treatment would benefit any particular patients included in these studies, researchers carried out an additional analysis following the main studies of GALATHEA and TERRANOVA. |
|---|---|
| ISSN: | 1753-4666 |